Ironwood Pharma (IRWD) Misses Q2 EPS by 16c ; Offers Guidance

Ironwood Pharma (NASDAQ: IRWD) reported Q2 EPS of $0.00, $0.16 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $94.39 million versus the consensus estimate of $107.1 million.

GUIDANCE:

Ironwood Pharma sees FY2024 revenue of $350-375 million, versus the consensus of $410.1 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• GameStop 'remains focused on advancing' proposed eBay deal, offers adjusted EBITDA guidance - Filing
• Deutsche Bank Downgrades Synaptics (SYNA) to Hold